Dynamic modulations of sphingolipids and glycerophospholipids in COVID‐19

• Published in: Clinical and translational medicine Vol. 12; no. 10; pp. e1069 - n/a
• Main Authors: Kurano, Makoto, Okamoto, Koh, Jubishi, Daisuke, Hashimoto, Hideki, Sakai, Eri, Saigusa, Daisuke, Kano, Kuniyuki, Aoki, Junken, Harada, Sohei, Okugawa, Shu, Doi, Kent, Moriya, Kyoji, Yatomi, Yutaka
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.10.2022; Wiley
• Subjects: Animals; Asymptomatic; Biomarkers; Ceramides; Clinical medicine; Coronaviruses; COVID-19; Discriminant analysis; Glycerophospholipids; Histones; Infectious diseases; Inflammation; lipidomics; Lipids; Lipopolysaccharides; Lysophosphatidylcholines; Mice; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylglycerols; Phosphatidylinositols; Severe acute respiratory syndrome coronavirus 2; severity; Sphingolipids; Sphingomyelins; Thromboplastin; COVID-19; severity; sphingolipids; lipidomics; glycerophospholipids

Background A heterogeneous clinical phenotype is a characteristic of coronavirus disease 2019 (COVID‐19). Therefore, investigating biomarkers associated with disease severity is important for understanding the mechanisms responsible for this heterogeneity and for developing novel agents to prevent c...